Senomorphics

Senomorphics, also called senostatics, are compounds that suppress the harmful secretory activity of senescent cells without killing them. They typically target signalling pathways that drive the SASP, including NF-kB, mTOR, JAK/STAT and p38 MAPK. Examples studied preclinically include rapamycin, metformin, ruxolitinib and certain flavonoids. The aim is to reduce chronic inflammation and tissue damage from senescent cells while preserving any beneficial roles they may have in wound healing and tumour suppression.